ELISA

Purespring Therapeutics presents preclinical data at the 61st ERA Congress

Retrieved on: 
金曜日, 5月 24, 2024
NPHS2, Patient, European Renal Association, Real-time, Glomerulosclerosis, Gene expression, Kidney, Kidney disease, Kidney bean, Liver, AAV, Messenger, Urine, Translational research, Therapy, ELISA, Chronic kidney disease, Congress, Blood, Gene, Podocyte, Proteinuria, Transgene, ERA, Serum albumin, Nephrotic syndrome, Vaccine

London— 24 May 2024— Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, is presenting preclinical data at the 61 st European Renal Association (ERA) Congress , showing that transgenes can be efficiently targeted to podocytes to replace defective genes or to use the podocyte as a protein factory to modulate kidney biology.

Key Points: 
  • London— 24 May 2024— Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, is presenting preclinical data at the 61 st European Renal Association (ERA) Congress , showing that transgenes can be efficiently targeted to podocytes to replace defective genes or to use the podocyte as a protein factory to modulate kidney biology.
  • The presentation: “A novel podocyte gene therapy enables pathway to clinical translation for the treatment of glomerular diseases” is being presented today at the ERA Congress, taking place in Stockholm, Sweden from 23-26 May.
  • This was demonstrated by resolution of severe proteinuria improved serum albumin and reduction in glomerulosclerosis.
  • Additional toxicological assessments of renal and other organ function from urine and blood, and post-study histopathological assessments revealed no pre-clinical treatment-related safety concerns.

Chlamydia Trachomatis and Neisseria Gonorrhoeae Tests Market Forecast to Surge Through 2033 Amid Increasing Diagnostic Demand - ResearchAndMarkets.com

Retrieved on: 
水曜日, 5月 8, 2024
Health, Infectious Diseases, Infection, ELISA, Chlamydia trachomatis, STI, Naʽat, Neisseria gonorrhoeae, COVID-19, Woman, Vaccine

The "Chlamydia Trachomatis and Neisseria Gonorrhoeae Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chlamydia Trachomatis and Neisseria Gonorrhoeae Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Chlamydia Trachomatis and Neisseria Gonorrhoeae tests is set to embark on a significant growth trajectory from 2020 extending through 2033.
  • With women and young adults between 15-24 years witnessing the most common occurrences, the tests market is experiencing a substantial uptick in demand.
  • Empowered by substantive insights and high-level analytics, the market for Chlamydia Trachomatis and Neisseria Gonorrhoeae tests underscores an optimistic outlook fueled by technological advancements and a deep-seated understanding of the clinical requirements.

Seek Labs Announces Successful Completion of African Swine Fever Virus In Vivo Trial Utilizing CRISPR-based Treatments

Retrieved on: 
月曜日, 5月 6, 2024
Research, Genetics, Clinical Trials, Other Health, Biotechnology, Health, Agriculture, Natural Resources, Science, Other Science, Mortality, African swine fever virus, Viral disease, CRISPR, Gene targeting, Hope, White, Chicken, Synthetic control method, Blood, ASF, Classical swine fever, Cas, ELISA, Animal, Survival, Litopenaeus, Infection, Doctor of Philosophy, Disease, ASFV, Real-time, Food security, Viral load, Food, Seek, H5N1, Genome, Candidate, Viral, Pharmacy, Injection, WSSV, Medication, Vaccine

Seek Labs, a healthcare innovations company developing next-generation point-of-care molecular diagnostic systems and novel CRISPR-based gene therapies, announced today the successful completion of a therapeutic trial using innovative CRISPR-based technologies to target the African Swine Fever Virus (ASFV) in pigs.

Key Points: 
  • Seek Labs, a healthcare innovations company developing next-generation point-of-care molecular diagnostic systems and novel CRISPR-based gene therapies, announced today the successful completion of a therapeutic trial using innovative CRISPR-based technologies to target the African Swine Fever Virus (ASFV) in pigs.
  • The trial, which aimed to replicate and expand an earlier trial, demonstrated pigs infected with ASFV and treated with Seek Labs’ CRISPR-based systems survived longer than untreated infected pigs.
  • With no available treatments for African Swine Fever, this is a breakthrough discovery.
  • Seek Labs’ work represents a beacon of hope for the swine industry and underscores the transformative potential of CRISPR-based technology in global healthcare.

Biomerica Reports Third Quarter 2024 Financial Results

Retrieved on: 
土曜日, 4月 13, 2024
Use, University, Insurance, Stomach, HP, Bacteria, ELISA, Helicobacter pylori, DDW, Clinical trial, Annual general meeting, US FDA, Growth, IBS

Although our operating expenses for the quarter were $0.1 million higher than the third quarter of 2023, primarily due to the strategic expansion of our sales force in fiscal year 2024, it is noteworthy that our operating expenses remained consistent with the second quarter of 2024.

Key Points: 
  • Although our operating expenses for the quarter were $0.1 million higher than the third quarter of 2023, primarily due to the strategic expansion of our sales force in fiscal year 2024, it is noteworthy that our operating expenses remained consistent with the second quarter of 2024.
  • As of February 29, 2024, the Company maintained a cash and equivalents balance of $5.3 million down from $7.1 million from fiscal second quarter of 2024.
  • Our gross margins improved to 13.7% from 9.9% within the year-to-date 2024 fiscal year compared to same period in 2023.
  • With the aforementioned focused management of operating expenses, net operating loss was 11% better in 2024 fiscal year compared to 2023.

Global Research Antibodies & Reagents Market Outlook & Forecasts, 2023 and 2024-2029: Growing Demand for Precision Medicine, Rising Focus on Biomarker Discovery, & Rise in Proteomics and Genomics - ResearchAndMarkets.com

Retrieved on: 
金曜日, 4月 12, 2024
Health, Stem Cells, Genetics, Research, Science, Biotechnology, USD, Immunoprecipitation, Antibody, Cancer, Genomics, Protein, Cell biology, ELISA, Heart, Personalized medicine, Proteomics, Immunohistochemistry, Biomedical Research, Biomarker, Growth, University, Disease, ChromeOS, Bio-Rad Laboratories, Therapy, Northern blot, Patient, Chemistry, Medicine, Diagnosis, Antigen, Gene expression, Genome, Elisa's, Drug development, Biology, Molecular biology, Drug discovery, Thermo Fisher Scientific, Gene, Flow cytometry, Fine chemical

North America holds the most prominent share of the global research antibodies & reagents market, accounting for over 39% in 2023.

Key Points: 
  • North America holds the most prominent share of the global research antibodies & reagents market, accounting for over 39% in 2023.
  • This paradigm shift presents a substantial opportunity for the research antibodies & reagents market, an essential component of precision medicine research.
  • The reagents product type accounted for the most significant global research antibodies & reagents market share in 2023.
  • The academics & research institutes and research labs end-user segment dominated the global research antibodies & reagents market share in 2023.

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024

Retrieved on: 
木曜日, 4月 25, 2024
Infection, Congress, Recombinant antibodies, SARS-CoV-2, Long, Viral, ELISA, ESCMID, Cytokine, Epitope, Lyme disease, Research, ELISpot, Immunology, Diagnosis, Long COVID, Biomarker, Immunity, Flow cytometry, CD8, Vaccine

The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.

Key Points: 
  • The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.
  • "We are very pleased to launch ImmuneSelect, an important portfolio of immune profiling solutions within our ViraxImmune™ T-Cell diagnostic platform," commented Mr. James Foster, Chief Executive Officer of Virax Biolabs.
  • "The launch marks a significant milestone for Virax as it brings us a step closer to commercializing ViraxImmune™ as a full In-Vitro-Diagnostic product."
  • ImmuneSelect is the Company's new portfolio of immune profiling solutions dedicated to investigating adaptive immunity.

Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test

Retrieved on: 
月曜日, 4月 22, 2024
Cancer, Risk, Pancreatic cancer, ELISA, Survival, EUS, Heredity, PDAC, Patient, MRI, Magnetic resonance imaging, CA19-9, Biomarker, Medical imaging

The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.

Key Points: 
  • The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.
  • Importantly, these results confirm the technical advancement of the next-generation test over Immunovia's first-generation test, IMMray PanCan-d.
  • Furthermore, the new test does not provide indeterminate or "borderline" results; all patients are classified as positive or negative for pancreatic cancer.
  • People at risk for pancreatic cancer need a simple, fast, and easy blood test to detect cancer early.

Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test

Retrieved on: 
月曜日, 4月 22, 2024
Cancer, Risk, Pancreatic cancer, ELISA, Survival, EUS, Heredity, PDAC, Patient, MRI, Magnetic resonance imaging, CA19-9, Biomarker, Medical imaging

The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.

Key Points: 
  • The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.
  • Importantly, these results confirm the technical advancement of the next-generation test over Immunovia's first-generation test, IMMray PanCan-d.
  • Furthermore, the new test does not provide indeterminate or "borderline" results; all patients are classified as positive or negative for pancreatic cancer.
  • People at risk for pancreatic cancer need a simple, fast, and easy blood test to detect cancer early.

BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS

Retrieved on: 
水曜日, 4月 10, 2024
ISH, FDA, Nature, Social media, ELISA, Cytokine, Gene editing, Conference, Research, Workflow, Diagnosis, CDT, Antibody, ACD, Drug discovery

The replay will be available from 11:00 a.m. CDT on Wednesday, May 1, 2024, until 11:00 p.m. CDT on Saturday, June 1, 2024.

Key Points: 
  • The replay will be available from 11:00 a.m. CDT on Wednesday, May 1, 2024, until 11:00 p.m. CDT on Saturday, June 1, 2024.
  • These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment.
  • With thousands of products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide.
  • For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook , LinkedIn , Twitter or YouTube .

Longhorn Vaccines and Diagnostics Presents at World Vaccine Congress on Advantages of Single Peptide Vaccine for Broad Coverage of Human and Avian Influenza Viruses

Retrieved on: 
火曜日, 4月 2, 2024
Health, Infectious Diseases, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Congress, Isotype, Influenza, Group 1, Public, Vaccine, Epitope, ELISA, Mouse, Immunoglobulin G, IND, Immunity, InvivoGen, Poster, Peptide

Results from the poster show that LHNVD-110 generated broadly reactive antibodies to human and highly pathogenic avian influenza viruses while neutralizing seasonal and pandemic influenza strains.

Key Points: 
  • Results from the poster show that LHNVD-110 generated broadly reactive antibodies to human and highly pathogenic avian influenza viruses while neutralizing seasonal and pandemic influenza strains.
  • This data mirrors previous studies with LHNVD-105, a dual peptide vaccines containing the same epitopes.
  • Using a single peptide provides a more cost-effective and easily scalable approach to such a universal influenza vaccine.
  • That is why using peptide-based vaccines with broad strain coverage may offer useful strategies towards preventing influenza, no matter the strain.